Company intelligence / Profile preview
Hualan Biological Vaccine Inc.
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
Overview
Hualan Biological Vaccine Inc. has a strong commercial presence with multiple approved human vaccines targeting influenza (including the world’s first marketed H1N1 split virion vaccine), hepatitis B (recombinant), meningococcus groups A/C/Y/W135 polysaccharide vaccines, rabies vaccine and others. The company’s recombinant hepatitis B vaccine has demonstrated safety and immunogenicity in clinical trials for infants/children. Products comply with international cGMP standards and have been distributed to over forty countries worldwide.[5][6][7][10]
- Therapeutic areas
- CardiovascularNeurologyInfectious Diseases
- Modalities
- Vaccines (bacterial and viral, including recombinant protein subunit vaccines)Genetic engineering vaccines
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Hualan Biological Vaccine Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hualan Biological Vaccine Inc..